FDA Inspection 1180710 — BlueRock Therapeutics LP

BlueRock Therapeutics LP — FEI 3014668323

The FDA completed an inspection of BlueRock Therapeutics LP on Aug 30, 2022 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Aug 30, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Bioresearch Monitoring
Location
Cambridge, MA (United States)

Additional Details

Sponsor, Contract Research Organization